OVID
Ovid TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
OVID Profile
Ovid Therapeutics Inc.
A biopharmaceutical company that develops medicines designed to conquer epilepsies
441 Ninth Avenue, 14th Floor, New York, New York 10001
--
Ovid Therapeutics Inc., was incorporated on April 1, 2014 under the laws of the State of Delaware. The company is a biopharmaceutical company focused on developing impactful drugs for patients and families with rare neurological diseases. The company believes that these diseases are an attractive area for drug development because the understanding of underlying biology has grown meaningfully over the past few years; but it is still ignored by the industry. Its experienced team has embarked on a vision of integrating the biology and symptoms of rare neurology, employing innovative research and clinical strategies for the development of its drug candidates. Using the latest scientific advances in genetics and biological pathways in the brain, the company has created a blueprint for disease-related pathways to identify and acquire new compounds for the treatment of rare neurological diseases. The company is executing its strategy to partner with leading biopharmaceutical companies and academic institutions in the licensing field. The company is developing a strong pipeline of clinical assets with an initial focus on neurodevelopmental disorders and rare epileptic encephalopathy.
